These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 33609715)

  • 1. Cell Tracking Suggests Pathophysiological and Therapeutic Role of Bone Marrow Cells in Sugen5416/Hypoxia Rat Model of Pulmonary Arterial Hypertension.
    Miwa H; Sakao S; Sanada TJ; Suzuki H; Hata A; Shiina Y; Kobayashi T; Kato F; Nishimura R; Tanabe N; Voelkel N; Yoshino I; Tatsumi K
    Can J Cardiol; 2021 Jun; 37(6):913-923. PubMed ID: 33609715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diverse contribution of bone marrow-derived cells to vascular remodeling associated with pulmonary arterial hypertension and arterial neointimal formation.
    Sahara M; Sata M; Morita T; Nakamura K; Hirata Y; Nagai R
    Circulation; 2007 Jan; 115(4):509-17. PubMed ID: 17242277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension.
    Corboz MR; Plaunt AJ; Malinin V; Li Z; Gauani H; Chun D; Cipolla D; Perkins WR; Chapman RW
    Eur J Pharmacol; 2022 Feb; 916():174484. PubMed ID: 34508752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Overview of the Biology and Pharmacology in Sugen/Hypoxia-Induced Pulmonary Hypertension in Rats.
    Corboz MR; Nguyen TL; Stautberg A; Cipolla D; Perkins WR; Chapman RW
    J Aerosol Med Pulm Drug Deliv; 2024 Oct; 37(5):241-283. PubMed ID: 39388691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haemodynamic unloading reverses occlusive vascular lesions in severe pulmonary hypertension.
    Abe K; Shinoda M; Tanaka M; Kuwabara Y; Yoshida K; Hirooka Y; McMurtry IF; Oka M; Sunagawa K
    Cardiovasc Res; 2016 Jul; 111(1):16-25. PubMed ID: 27037259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of treprostinil in the SU5416-hypoxia model of severe pulmonary arterial hypertension: haemodynamic benefits are not associated with improvements in arterial remodelling.
    Chaudhary KR; Deng Y; Suen CM; Taha M; Petersen TH; Mei SHJ; Stewart DJ
    Br J Pharmacol; 2018 Oct; 175(20):3976-3989. PubMed ID: 30098019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
    Honda Y; Kosugi K; Fuchikami C; Kuramoto K; Numakura Y; Kuwano K
    PLoS One; 2020; 15(10):e0240692. PubMed ID: 33057388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Injury-Induced Shedding of Extracellular Vesicles Depletes Endothelial Cells of Cav-1 (Caveolin-1) and Enables TGF-β (Transforming Growth Factor-β)-Dependent Pulmonary Arterial Hypertension.
    Oliveira SDS; Chen J; Castellon M; Mao M; Raj JU; Comhair S; Erzurum S; Silva CLM; Machado RF; Bonini MG; Minshall RD
    Arterioscler Thromb Vasc Biol; 2019 Jun; 39(6):1191-1202. PubMed ID: 30943774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capillary Degeneration and Right Ventricular Remodeling Due to Hypoxic Stress with Sugen5416.
    Woo E; Kato R; Imano H; Fujiwara Y; Ijiri Y; Okada Y; Yamaguchi T; Izumi Y; Yoshiyama M; Katsumata T; Hayashi T
    Curr Vasc Pharmacol; 2017; 15(6):589-598. PubMed ID: 28460626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.
    Rol N; de Raaf MA; Sun XQ; Kuiper VP; da Silva Gonçalves Bos D; Happé C; Kurakula K; Dickhoff C; Thuillet R; Tu L; Guignabert C; Schalij I; Lodder K; Pan X; Herrmann FE; van Nieuw Amerongen GP; Koolwijk P; Vonk-Noordegraaf A; de Man FS; Wollin L; Goumans MJ; Szulcek R; Bogaard HJ
    Cardiovasc Res; 2019 Feb; 115(2):432-439. PubMed ID: 30032282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRPC4 inactivation confers a survival benefit in severe pulmonary arterial hypertension.
    Alzoubi A; Almalouf P; Toba M; O'Neill K; Qian X; Francis M; Taylor MS; Alexeyev M; McMurtry IF; Oka M; Stevens T
    Am J Pathol; 2013 Dec; 183(6):1779-1788. PubMed ID: 24113457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BMPR2-expressing bone marrow-derived endothelial-like progenitor cells alleviate pulmonary arterial hypertension in vivo.
    Harper RL; Maiolo S; Ward RJ; Seyfang J; Cockshell MP; Bonder CS; Reynolds PN
    Respirology; 2019 Nov; 24(11):1095-1103. PubMed ID: 30977250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow-derived cells contribute to pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension.
    Hayashida K; Fujita J; Miyake Y; Kawada H; Ando K; Ogawa S; Fukuda K
    Chest; 2005 May; 127(5):1793-8. PubMed ID: 15888860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of JAK2 protects mice against hypoxia-induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation.
    Zhang L; Wang Y; Wu G; Rao L; Wei Y; Yue H; Yuan T; Yang P; Xiong F; Zhang S; Zhou Q; Chen Z; Li J; Mo BW; Zhang H; Xiong W; Wang CY
    Cell Prolif; 2020 Feb; 53(2):e12742. PubMed ID: 31943454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban Attenuates Right Ventricular Remodeling in Rats with Pulmonary Arterial Hypertension.
    Imano H; Kato R; Nomura A; Tamura M; Yamaguchi Y; Ijiri Y; Wu H; Nakano T; Okada Y; Yamaguchi T; Izumi Y; Yoshiyama M; Asahi M; Hayashi T
    Biol Pharm Bull; 2021 May; 44(5):669-677. PubMed ID: 33612567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Isoquinoline-Sulfonamide Compound H-1337 Attenuates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension in Rats.
    Shoji H; Yoshida Y; Sanada TJ; Naito A; Maruyama J; Zhang E; Sumi K; Sakao S; Maruyama K; Hidaka H; Tatsumi K
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired Pulmonary Arterial Vasoconstriction and Nitric Oxide-Mediated Relaxation Underlie Severe Pulmonary Hypertension in the Sugen-Hypoxia Rat Model.
    Christou H; Hudalla H; Michael Z; Filatava EJ; Li J; Zhu M; Possomato-Vieira JS; Dias-Junior C; Kourembanas S; Khalil RA
    J Pharmacol Exp Ther; 2018 Feb; 364(2):258-274. PubMed ID: 29212831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of mesenchymal stem cell delivery via a novel cardiac bioscaffold on right ventricles of pulmonary arterial hypertensive rats.
    Schmuck EG; Hacker TA; Schreier DA; Chesler NC; Wang Z
    Am J Physiol Heart Circ Physiol; 2019 May; 316(5):H1005-H1013. PubMed ID: 30822119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered Macrophage Polarization Induces Experimental Pulmonary Hypertension and Is Observed in Patients With Pulmonary Arterial Hypertension.
    Zawia A; Arnold ND; West L; Pickworth JA; Turton H; Iremonger J; Braithwaite AT; Cañedo J; Johnston SA; Thompson AAR; Miller G; Lawrie A
    Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):430-445. PubMed ID: 33147993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temporal hemodynamic and histological progression in Sugen5416/hypoxia/normoxia-exposed pulmonary arterial hypertensive rats.
    Toba M; Alzoubi A; O'Neill KD; Gairhe S; Matsumoto Y; Oshima K; Abe K; Oka M; McMurtry IF
    Am J Physiol Heart Circ Physiol; 2014 Jan; 306(2):H243-50. PubMed ID: 24240870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.